CTX
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
Created: | 2005-01-14 |
Last modified: | 2021-03-01 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 57 |
Chiral Atom Count | 0 |
Bond Count | 59 |
Aromatic Bond Count | 18 |
Chemical Component Summary | |
---|---|
Name | (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE |
Synonyms | TRANS FORM OF TAMOXIFEN |
Systematic Name (OpenEye OEToolkits) | 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethyl-ethanamine |
Formula | C26 H29 N O |
Molecular Weight | 371.515 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O(c1ccc(cc1)/C(c2ccccc2)=C(\c3ccccc3)CC)CCN(C)C |
SMILES | CACTVS | 3.341 | CCC(c1ccccc1)=C(c2ccccc2)c3ccc(OCCN(C)C)cc3 |
SMILES | OpenEye OEToolkits | 1.5.0 | CCC(=C(c1ccccc1)c2ccc(cc2)OCCN(C)C)c3ccccc3 |
Canonical SMILES | CACTVS | 3.341 | CC/C(c1ccccc1)=C(c2ccccc2)/c3ccc(OCCN(C)C)cc3 |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | CC/C(=C(\c1ccccc1)/c2ccc(cc2)OCCN(C)C)/c3ccccc3 |
InChI | InChI | 1.03 | InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- |
InChIKey | InChI | 1.03 | NKANXQFJJICGDU-QPLCGJKRSA-N |
Drug Info: DrugBank
DrugBank ID | DB00675 |
---|---|
Name | Tamoxifen |
Groups | approved |
Description | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].[A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799] |
Synonyms |
|
Brand Names |
|
Indication | Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.[L7802] |
Categories |
|
ATC-Code | L02BA01 |
CAS number | 10540-29-1 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Estrogen receptor | MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPA... | unknown | antagonist,agonist |
Estrogen receptor beta | MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHHEYPAMTFYS... | unknown | antagonist,agonist |
Protein kinase C | MADVFPGNDSTASQDVANRFARKGALRQKNVHEVKDHKFIARFFKQPTFC... | unknown | inhibitor |
Sex hormone-binding globulin | MESRGPLATSRLLLLLLLLLLRHTRQGWALRPVLPTQSAHDPPAVHLSNG... | unknown | inducer |
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | MTTNAGPLHPYWPQHLRLDNFVPNDRPTWHILAGLFSVTGVLVVTTWLLS... | unknown | inhibitor |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL83 |
PubChem | 2733526 |
ChEMBL | CHEMBL83 |
ChEBI | CHEBI:41774 |
CCDC/CSD | FUPDOJ, FUPDOJ01 |